Figure 5
Quality of life, EHRA AF symptom score, arrhythmia-related symptoms (baseline—12 months). (A) AFEQT score improvement. (B) AFEQT score improvement with and without recurrence. (C) EHRA symptom score reduction. (D) Arrhythmia-related symptom reduction. aChange ≥19, meaningful clinical improvement.20 *P < 0.0001; **Kruskal–Wallis test. AFEQT , Atrial Fibrillation Effect on QualiTy-of-Life; FU, follow-up; Mo, month.AQ16

Quality of life, EHRA AF symptom score, arrhythmia-related symptoms (baseline—12 months). (A) AFEQT score improvement. (B) AFEQT score improvement with and without recurrence. (C) EHRA symptom score reduction. (D) Arrhythmia-related symptom reduction. aChange ≥19, meaningful clinical improvement.20 *P < 0.0001; **Kruskal–Wallis test. AFEQT , Atrial Fibrillation Effect on QualiTy-of-Life; FU, follow-up; Mo, month.AQ16

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close